Tobias Peters, Immanuel Philipp Seitz, Stylianos Michalakis, Martin Biel, Barbara Wilhelm, Felix Friedrich Reichel, Guy Alexander Ochakovski, Eberhart Zrenner, Marius Ueffing, Birgit Korbmacher, Sven Korte, Karl Ulrich Bartz-Schmidt, Manuel Dominik Fischer, Consortium Rd-Cure
The purpose of this study was to examine the toxicity and side effects of a recombinant AAV8 vector, aimed to treat CNGA3-linked achromatopsia, after a single subretinal administration in cynomolgus macaques. Animals were followed in two studies: a 13-week study with 22 animals and a 28-day study with 12 animals. Both groups were divided into subgroups receiving either vehicle only, a low (1x1011 vector genomes (vg)), or a high dose (1x1012 vg) of rAAV.hCNGA3. In the 13-week study, an extra group received single high dose intravitreal injections...
March 13, 2019: Human Gene Therapy. Clinical Development